samedan logo
 
 
spacer
home > pmps > spring 2003 > taking the tribulations out of the trials - an examination of the role of the validated cold chain shipper in clinical trials
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Taking the Tribulations Out of the Trials - An Examination of the Role of the Validated Cold Chain Shipper in Clinical Trials

Everybody who has ever been involved in a clinical trial will be aware of how every stage of the operation, and every component part of the exercise, has to be checked and re-checked with much rigour. This is because the failure of any one part of the exercise can be apocalyptic in its impact. It can bar the route to market, delay approvals, let in the competition and cost millions - both in lost revenues and dipping share prices. In addition there are the human and social dimensions of failing to get a medicinal product to market.

Increasingly more and more of these kinds of product need controlled storage and transit conditions and the most cursory examination of the evidence shows that one of the biggest problems facing anybody running a clinical trial lies in defects in the distribution chain. A significant problem in the commercial distribution of pharmaceutical products, this becomes magnified in a trial situation.

The extent of the problem can be judged from the findings of the WHO: 25 per cent of all vaccines transported by air cargo will not give the protection intended because of defective cold chains. Whilst according to the UK's Medicines Control Agency no less than 35 per cent of all deficiencies recorded by the inspectors auditing pharmaceutical wholesale distributors in the UK related to the control and monitoring of storage transit temperatures.



Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Tim Jennings, Sales Manager at Laminar Medica Ltd

Tim Jennings is the Sales Manager at Laminar Medica Ltd. He has five years' experience in designing cold chain validations and insulated shipping systems. Prior to managing the sales function at Laminar Medica, Tim worked in engineering design of pharmaceutical plants.

spacer
Tim Jennings
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Biognosys Announces the Launch of its Next-Generation Plasma Biomarker Discovery Solution

October 5th, 2021 SCHLIEREN, (Zurich, Switzerland). Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, today announces the upcoming launch of its next-generation plasma biomarker discovery solution.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement